{
    "clinical_study": {
        "@rank": "80755", 
        "arm_group": [
            {
                "arm_group_label": "Vilazodone 20 mg", 
                "arm_group_type": "Experimental", 
                "description": "Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 28 days."
            }, 
            {
                "arm_group_label": "Vilazodone 40 mg", 
                "arm_group_type": "Experimental", 
                "description": "Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 7 days,  followed by vilazodone 40 mg once daily for 21 days"
            }, 
            {
                "arm_group_label": "Paroxetine 20 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Paroxetine 10 mg once daily for 7 days, followed by paroxetine 20 mg for 28 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo once daily for 35 days"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the effects of vilazodone, paroxetine and placebo on sexual function in sexually\n      active healthy adults."
        }, 
        "brief_title": "Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or female, aged 18 through 45 years, inclusive\n\n          -  Currently sexually active\n\n          -  If female, non pregnant and agree to use acceptable for of contraception during\n\n          -  If male, be sterile or have partner use contraception.\n\n        Exclusion Criteria:\n\n          -  Have sexual dysfunction\n\n          -  Have history of diagnosis or treatment of any disorder related to sexual functioning.\n\n          -  Clinically significant disease state, in the opinion of the examining physician, in\n             any body system\n\n          -  History of alcohol or other substance abuse or dependence within the previous 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097147", 
            "org_study_id": "VLZ-MD-24"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vilazodone 20 mg", 
                "description": "Oral administration, once per day.", 
                "intervention_name": "Vilazodone 20 mg", 
                "intervention_type": "Drug", 
                "other_name": "Viibyrd"
            }, 
            {
                "arm_group_label": "Vilazodone 40 mg", 
                "description": "Oral administration, once per day.", 
                "intervention_name": "Vilazodone 40 mg", 
                "intervention_type": "Drug", 
                "other_name": "Viibryd"
            }, 
            {
                "arm_group_label": "Paroxetine 20 mg", 
                "description": "Oral administration, once per day.", 
                "intervention_name": "Paroxetine 20 mg", 
                "intervention_type": "Drug", 
                "other_name": "Paxil"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Oral administration, once per day.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paroxetine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Viibryd", 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }, 
                    "name": "Forest Investigative Site 001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66212"
                    }, 
                    "name": "Forest Investigative Site 002"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Paul", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55114"
                    }, 
                    "name": "Forest Investigative Site 003"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22903"
                    }, 
                    "name": "Forest Investigative Site 004"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multi-Center, Randomized, Double-Blind, Parallel-Group Study Evaluating The Sexual Functioning of Healthy Adults After Receiving Multiple-Dose Regimens of Vilazodone, Paroxetine, or Placebo", 
        "overall_contact": {
            "email": "FRXClinTrials@frx.com", 
            "last_name": "Sandra Beaird, Pharm.D", 
            "phone": "1-800-678-1605", 
            "phone_ext": "66297"
        }, 
        "overall_official": {
            "affiliation": "Forest Laboratories", 
            "last_name": "Maju Mathews, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The CSFQ is a subject-rated scale designed to measure changes in sexual function and is a structured, self-report, 14-item questionnaire, that measures sexual functioning as a total score (all 14 items), and on the subscales of pleasure, desire/frequency, desire/interest, arousal, and orgasm, rated on a 5 point scale, with each item rated from 1 to 5, and a total score range of 14 to 70. Lower scores are associated with worsened sexual functioning.", 
            "measure": "Change in Changes in Sexual Functioning Questionnaire (CSFQ) total score", 
            "safety_issue": "Yes", 
            "time_frame": "From Baseline to Day 35"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097147"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Proportion of subjects meeting criteria for sexual dysfunction (ie, CSFQ <=47 for males and <=41 for females) at any 2 consecutive visits during the double-blind treatment period.", 
            "measure": "Proportion of subjects meeting criteria for sexual dysfunction.", 
            "safety_issue": "Yes", 
            "time_frame": "5 Weeks"
        }, 
        "source": "Forest Laboratories", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Forest Laboratories", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}